Currently there are five major companies that have approved branded drugs in the...
- Deals this week: Pharmaxis, Almirall, Cipla Quality Chemical Industries
- Spark Therapeutics Q2 financial results: income growth helped by US launch of Luxturna
- Mylan Q2 financial results: revenue decline led by falling sales in North America
- The next generation of antimalarials
- Deals this week: Daiichi Sankyo, MannKind, Dova Pharmaceuticals
SIRION Biotech’s NextGenAAV is a full customisation service for gene therapy research and development (R&D). The company can optimise adeno-associated virus (AAV) tissue specificity and immunogenic profile.
Fast and Reliable Quantification of Data
Omnian was developed for Malvern Panalytical's high-end x-ray fluorescence (XRD) spectrometer and is also available for the Epsilon 4 energy dispersive x-ray fluorescence (EDXRF) benchtop systems. This powerful combination brings together the strengths of Omnian with the ease-of-use of Epsilon 4.
Deals this week: Pharmaxis, Almirall, Cipla Quality Chemical Industries
Pharmaxis has raised A$24m ($17.74m) in two tranches through a private placement of 73.8 million shares priced at A$0.325 ($0.24) a share.
Spark Therapeutics Q2 financial results: income growth helped by US launch of Luxturna
US-based gene therapy company Spark Therapeutics has reported $25.2m in revenue, $80.2m in net income and $2.15 basic income per common share in the second quarter (Q2) of 2018.
Mylan Q2 financial results: revenue decline led by falling sales in North America
Global healthcare company Mylan has reported its revenue declined by 5% in the second quarter (Q2) of 2018 to $2.81bn with net sales in North America falling by 22% to $1bn.
Pharma air freight: what does it take to get certified?
Swissport Cargo Services has been awarded CEIV Pharma certification for pharmaceutical logistics by the International Airport Transport Association (IATA) at its Basel EuroAirport freight hub. Sally Turner speaks to IATA and Swissport, which has now received pharma logistics certification at six of its facilities, to discuss the latest requirements for freight hubs that prepare pharma products for transport by air.
FDA approves Vertex’s cystic fibrosis therapy Orkambi for children under six
The US Food and Drug Administration (FDA) has granted approval to Vertex Pharmaceuticals for the use of its Orkambi (lumacaftor/ivacaftor) medicine to treat cystic fibrosis in children between two and five years old.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.